Protalix BioTherapeutics Analyst Ratings
Protalix BioTherapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 669.23% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
10/31/2023 | 669.23% | HC Wainwright & Co. | $7 → $10 | Maintains | Buy |
05/03/2021 | 438.46% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
06/08/2020 | 746.15% | HC Wainwright & Co. | $3 → $11 | Maintains | Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/14/2023 | 669.23% | HC Wainwright & Co. | → 10 美元 | 重申 | 购买 → 购买 |
10/31/2023 | 669.23% | HC Wainwright & Co. | 7 美元 → 10 美元 | 维护 | 买 |
05/03/2021 | 438.46% | HC Wainwright & Co. | 11 美元 → 7 美元 | 维护 | 买 |
06/08/2020 | 746.15% | HC Wainwright & Co. | 3 美元 → 11 美元 | 维护 | 买 |
What is the target price for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics(PLX)的目标价格是多少?
The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 669.23% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了Protalix BioTherapeutics(美国证券交易所股票代码:PLX)的最新目标价格。该分析公司将目标股价定为10.00美元,预计PLX将在12个月内升至12个月内(可能上涨669.23%)。去年有两家分析公司公布了评级。
What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics(PLX)的最新分析师评级是多少?
The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Protalix BioTherapeutics(美国证券交易所股票代码:PLX)的最新分析师评级,Protalix BioTherapeutics重申了其买入评级。
When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics(PLX)的下一次分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Protalix BioTherapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Protalix BioTherapeutics的最新评级是在2023年11月14日公布的,因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?
分析师对Protalix BioTherapeutics(PLX)的评级是否正确?
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.30, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Protalix BioTherapeutics(PLX)评级得到了重申,目标股价为0.00美元至10.00美元。Protalix BioTherapeutics(PLX)目前的交易价格为1.30美元,在分析师的预测区间内。